We are live on
!
Find out more
GA
Geneva Advisors Portfolio holdings
AUM
$5.81B
Turnover
22.5%
1-Year Est. Return
23.71%
This Fund
S&P 500
This Quarter
Est. Return
+1.58%
1 Year Est. Return
+23.71%
3 Year Est. Return
+53.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.12B
AUM Growth
-$199M
(-3.7%)
Cap. Flow
-$200M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
24.54%
Holding
885
New
102
Increased
287
Reduced
309
Closed
94
Avg Time Held
1.8
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$25.9M |
| 2 |
Citizens Financial Group
CFG
|
+$23.8M |
| 3 |
EOG Resources
EOG
|
+$23.7M |
| 4 |
Independent Bank Group, Inc.
IBTX
|
+$18.4M |
| 5 |
Acuity Brands
AYI
|
+$17.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BEAV
B/E Aerospace Inc
BEAV
|
+$48.6M |
| 2 |
Ventas
VTR
|
+$42.2M |
| 3 |
Centene
CNC
|
+$38.9M |
| 4 |
Manhattan Associates
MANH
|
+$30.4M |
| 5 |
Salesforce
CRM
|
+$24.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.09% |
| 2 | Financials | 14.79% |
| 3 | Technology | 14.28% |
| 4 | Consumer Discretionary | 14.11% |
| 5 | Industrials | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
251
Eli Lilly
LLY
$1.12T
| $1.5M | 0.03% |
20,396
-770
| -4% | -$57.3K |
2013 Q2
14 quarters
|
|
252
Toyota
TM
$226B
| $1.5M | 0.03% |
12,791
-1,112
| -8% | -$130K |
2014 Q4
8 quarters
|
|
|
CEB
253
DELISTED
CEB Inc.
CEB
| $1.48M | 0.03% |
24,424
+135
| +0.6% | +$7.45K |
2013 Q2
14 quarters
|
|
254
Fomento Económico Mexicano
FMX
$41.2B
| $1.45M | 0.03% |
18,962
-981
| -5% | -$84K |
2014 Q1
11 quarters
|
|
|
CERN
255
DELISTED
Cerner Corp
CERN
| $1.44M | 0.03% |
30,352
-1,705
| -5% | -$90.5K |
2014 Q1
11 quarters
|
|
256
Nucor
NUE
$57.8B
| $1.41M | 0.03% |
23,755
+15,270
| +180% | +$854K |
2016 Q3
1 quarter
|
|
257
DELISTED
ENVESTNET, INC.
ENV
| $1.41M | 0.03% |
40,000
+2,058
| +5% | +$73.8K |
2013 Q2
14 quarters
|
|
258
DELISTED
Monroe Capital Corp
MRCC
| $1.39M | 0.03% |
90,146
+11,427
| +15% | +$172K |
2015 Q4
4 quarters
|
|
259
The Mosaic Company
MOS
$6.02B
| $1.35M | 0.03% |
46,098
+12,652
| +38% | +$339K |
2013 Q2
14 quarters
|
|
260
Roper Technologies
ROP
$37.8B
| $1.32M | 0.03% |
7,229
-894
| -11% | -$160K |
2014 Q1
11 quarters
|
|
261
Thermo Fisher Scientific
TMO
$258B
| $1.31M | 0.03% |
9,291
-1,244
| -12% | -$183K |
2015 Q2
6 quarters
|
|
262
Veeva Systems
VEEV
$50.7B
| $1.3M | 0.03% |
32,022
+37
| +0.1% | +$1.51K |
2016 Q2
2 quarters
|
|
263
Core Laboratories
CLB
$449M
| $1.29M | 0.03% |
10,730
+2,482
| +30% | +$275K |
2013 Q2
14 quarters
|
|
264
Main Street Capital
MAIN
$5.07B
| $1.29M | 0.03% |
34,994
+6,095
| +21% | +$215K |
2015 Q4
4 quarters
|
|
265
Rio Tinto
RIO
$147B
| $1.28M | 0.03% |
33,345
-7,693
| -19% | -$282K |
2015 Q2
6 quarters
|
|
|
STJ
266
DELISTED
St Jude Medical
STJ
| $1.28M | 0.02% |
15,936
+96
| +0.6% | +$7.62K |
2013 Q2
14 quarters
|
|
|
LDL
267
DELISTED
Lydall, Inc.
LDL
| $1.27M | 0.02% |
20,502
+2,555
| +14% | +$141K |
2016 Q1
3 quarters
|
|
|
NJ
268
DELISTED
NIDEC CP (NIHON KABUSHIKI KAISHA)1 ADS REPTG .25 SH COM STK
NJ
| $1.26M | 0.02% |
58,905
-2,110
| -3% | -$45.2K |
2015 Q1
7 quarters
|
|
269
Vanguard FTSE Europe ETF
VGK
$29.7B
| $1.26M | 0.02% |
26,246
-32,908
| -56% | -$1.55M |
2015 Q3
5 quarters
|
|
270
LKQ Corp
LKQ
$5.66B
| $1.25M | 0.02% |
40,860
-1,600
| -4% | -$52.2K |
2013 Q2
14 quarters
|
|
271
Ares Capital
ARCC
$13.6B
| $1.24M | 0.02% |
75,387
+8,802
| +13% | +$139K |
2014 Q1
11 quarters
|
|
272
Everforth Inc
EFOR
$1.62B
| $1.24M | 0.02% |
27,977
+1,360
| +5% | +$54.1K |
2013 Q2
14 quarters
|
|
273
Vanguard Dividend Appreciation ETF
VIG
$113B
| $1.23M | 0.02% |
14,492
+3,478
| +32% | +$292K |
2013 Q2
14 quarters
|
|
274
Waste Management
WM
$89.6B
| $1.23M | 0.02% |
17,402
+1,139
| +7% | +$76.2K |
2013 Q2
14 quarters
|
|
275
Forward Air
FWRD
$535M
| $1.23M | 0.02% |
25,939
+1,457
| +6% | +$66.7K |
2015 Q3
5 quarters
|
|
Similar funds
CAM
DL
TCM
HCM
AL
AT
Geneva Advisors's Q4 2016 Portfolio in Review
As of Q4 2016, Geneva Advisors held 885 positions worth $5.12B, down 3.7% from $5.32B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Geneva Advisors withdrew a net $200M in Q4 2016, closing 94 positions and reducing 309 holdings. Its most notable exit was Ventas, an estimated $42.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 18% a quarter earlier, followed by Financials and Technology.
Against the trend, Geneva Advisors opened a new position in Citizens Financial Group worth $28M.
- Geneva Advisors's largest Q4 2016 buy was Citizens Financial Group: 786,703 shares worth $28M.
- Geneva Advisors added most to Celgene Corp in Q4 2016, an estimated $25.9M increase.
- Geneva Advisors's biggest Q4 2016 reduction was B/E Aerospace Inc, cutting an estimated $48.6M.
- Geneva Advisors fully exited Ventas in Q4 2016, selling an estimated $42.2M.
- Geneva Advisors's ten largest holdings make up 25% of its $5.12B portfolio in Q4 2016.
- Geneva Advisors opened 102 new positions and closed 94 in Q4 2016.
- Geneva Advisors's portfolio value fell 3.7% quarter-over-quarter to $5.12B.
Based on Geneva Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.